Mechanisms of Disease: selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome

This publication has 56 references indexed in Scilit:

• Meta-Analysis: Pharmacologic Treatment of Obesity
  Annals of Internal Medicine, 2005
• Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
  The Lancet, 2005
• Inhibition of Food Intake in Obese Subjects by Peptide YY_3–36
  New England Journal of Medicine, 2003
• A Transgenic Model of Visceral Obesity and the Metabolic Syndrome
  Science, 2001
• Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults
  New England Journal of Medicine, 1999
• The N-terminal Anchor Sequences of 11β-Hydroxysteroid Dehydrogenases Determine Their Orientation in the Endoplasmic Reticulum Membrane
  Journal of Biological Chemistry, 1999
• Cortisol Effects on Body Mass, Blood Pressure, and Cholesterol in the General Population
  Hypertension, 1999
• 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress
  Proceedings of the National Academy of Sciences, 1997
• Cholesterol Lowering With Statin Drugs, Risk of Stroke, and Total Mortality
  JAMA, 1997
• Expression of 11β-Hydroxysteroid Dehydrogenase Using Recombinant Vaccinia Virus
  Molecular Endocrinology, 1990